Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

Inclusion criteria: * Signed informed consent. * Histologically or cytologically confirmed diagnosis of advanced solid tumor. * Women and men with potential to have children must be willing to practice acceptable methods of birth control during the study. * ECOG performance status of 0 or 1. * Adequate bone marrow reserve and hepato-renal function. * Able to swallow and retain oral medication. * For combo part, left ventricular ejection fraction within normal range or above 50%. Exclusion criteria: * Prior treatment with pazopanib, and with lapatinib for combo part. * Clinically significant gastrointestinal abnormalities. * Sevier diseases or conditions other than cancer. * Poorly controlled hypertension. * Use of warfarin for therapeutic anticoagulation. * Use of other anti-angiogenesis agents, and other ErbB inhibitors for combo part. * Unresolved and/or unstable toxicities * Pregnant or lactating females